The U.S. Securities and Exchange Commission has ushered in a new era for the accounting watchdog, naming a fresh chair and three board members tasked with refocusing the PCAOB on its core mission of investor protection.
Facing pressure from both investors and regulators, banks and wealth managers are turning to pass-through voting mechanisms to reclaim shareholder influence and align stewardship with client values, even within passively managed funds.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
Major financial institutions Barclays and Morgan Stanley maintain projections for two interest rate cuts in 2024, despite President Trump's nomination of inflation hawk Kevin Warsh to chair the Federal Reserve. Analysts suggest policy continuity in the near term, though Senate confirmation faces political hurdles.
As United Parcel Service executes a strategic overhaul focused on profitability over volume, its financials reveal a nascent but promising trend, leading some investors to see a potential rebound on the horizon despite recent stock declines.
Despite a volatile post-earnings reaction, Invesco Ltd. maintains robust analyst support with upgraded ratings and bullish price targets, as the asset manager's strategic moves and inflows fuel optimism.
The parent company of Fatburger and Round Table Pizza, along with its Twin Hospitality spinoff, will be removed from the Nasdaq exchange effective February 4, transitioning to the over-the-counter market following Chapter 11 filings and over $1 billion in debt.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
Specialty insurer Kinsale Capital Group continues to outpace broader industry growth in key metrics, driven by its focus on underserved, higher-risk markets. However, its premium valuation and recent stock volatility have intensified debate among investors about its long-term sustainability.
Despite a sharp sell-off in its shares, HubSpot reports a surge in new contract signings and projects an expanding free cash flow margin, signaling underlying operational strength even as investors remain wary.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
A highly sensitive whistleblower complaint alleging misconduct by Director of National Intelligence Tulsi Gabbard has been locked within the intelligence bureaucracy since May, with Congress aware of its existence but blocked from reviewing it amid accusations of obstruction.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Wall Street's top analysts made waves Monday with revised ratings on key stocks, highlighting a growing divergence in tech and retail outlooks as earnings season approaches.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
